Endothelin-receptor antagonists for diabetic nephropathy: A meta-analysis

Nephrology

Volumn 20, Issue 7, 2015, Pages 459-466

  Yuan, Wenming ^a   Li, Yi ^b   Wang, Ji ^a   Li, Jing ^a   Gou, Shenju ^a   Fu, Ping ^a  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

diabetic nephropathy; endothelin receptor antagonists; meta analysis

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO;

ACUTE HEART INFARCTION; ALBUMINURIA; ANEMIA; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ESTIMATED GLOMERULUS FILTRATION RATE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERVOLEMIA; HYPOTENSION; META ANALYSIS; MORTALITY; NONFATAL ACUTE MYOCARDIAL INFARCTION; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; DIABETIC NEPHROPATHIES;

DIABETIC NEPHROPATHIES; ENDOTHELIN RECEPTOR ANTAGONISTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84930738394     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12442     Document Type: Conference Paper

References (18)

1. Remuzzi G, Benigni A, Remuzzi A,. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 2006; 116: 288-296.
2. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC,. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst. Rev. 2006; D6257.
3. Tobe SW, Clase CM, Gao P, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011; 123: 1098-1107.
4. Kohan DE,. Endothelin, hypertension and chronic kidney disease: new insights. Curr. Opin. Nephrol. Hypertens. 2010; 19: 134-139.
5. Neuhofer W, Pittrow D,. Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence. Eur. J. Clin. Invest. 2009; 39 (Suppl 2): 50-67.
6. Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM,. Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes. Diabetologia 2011; 54: 979-988.
7. Cai L, Chen S, Evans T, Cherian MG, Chakrabarti S,. Endothelin-1-mediated alteration of metallothionein and trace metals in the liver and kidneys of chronically diabetic rats. Int. J. Exp. Diabetes Res. 2002; 3: 193-198.
8. Kohan DE, Pritchett Y, Molitch M, et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J. Am. Soc. Nephrol. 2011; 22: 763-772.
9. Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J. Am. Soc. Nephrol. 2010; 21: 527-535.
10. de Zeeuw D, Coll B, Andress D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 2014; 25: 1083-1093.
11. Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Cochrane Collabor. 2011 [Cited 2015 Feb.] Available from URL: http://handbook.cochrane.org/
12. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: the nordic cochrane centre. Cochrane Collabor. 2014 Available from URL: http://community.cochrane.org/editorial-and-publishing-policy-resource/review-manager-revman
13. Rafnsson A, Bohm F, Settergren M, Gonon A, Brismar K, Pernow J,. The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial. Diabetologia 2012; 55: 600-607.
14. Wenzel RR, Littke T, Kuranoff S, et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J. Am. Soc. Nephrol. 2009; 20: 655-664.
15. Abdelsaid M, Kaczmarek J, Coucha M, Ergul A,. Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: relevance to glycemic control. Life Sci. 2014; 118: 268-273. Available from: http://dx.doi.org/10.1016/j.lfs.2014.01.008
16. Angelousi A, Girerd N, Benetos A, et al. Association between orthostatic hypotension and cardiovascular risk, cerebrovascular risk, cognitive decline and falls as well as overall mortality: a systematic review and meta-analysis. J. Hypertens. 2014; 32: 1562-1571.
17. Sica DA,. Edema mechanisms in the patient with heart failure and treatment options. Heart Fail Clin. 2008; 4: 511-518.
18. Reichetzeder C, Tsuprykov O, Hocher B,. Endothelin receptor antagonists in clinical research-lessons learned from preclinical and clinical kidney studies. Life Sci. 2014; 118: 141-148. Available from: http://dx.doi.org/10.1016/j.lfs.2014.02.025